BACKGROUND/AIMS: Glycogen storage disease type Ib (GSD-Ib) patients deficient in a glucose-6-phosphate transporter (G6PT) manifest disturbed glucose homeostasis, myeloid dysfunctions, and hepatocellular adenoma (HCA). This study was conducted to evaluate whether maintaining normoglycemia in GSD-Ib could prevent HCA. METHODS: We infused neonatal GSD-Ib mice with adeno-associated virus (AAV) carrying G6PT and examined their metabolic and myeloid phenotypes for the 72-week study. RESULTS: The AAV vector delivered the G6PT transgene to the liver and bone marrow. Long-term metabolic correction was achieved alongside a transient myeloid correction. Hepatic G6PT activity was 50% of wild-type levels at 2 weeks post-infusion but declined rapidly thereafter to reach 3% of wild-type levels by age 6 to 72 weeks. Despite this, the infused mice maintained normoglycemia throughout the study, exhibited near normal growth and normalized serum metabolite profiles. However, all five AAV-treated GSD-Ib mice that lived over 50 weeks accumulated excessive hepatic glycogen and fat. Two mice developed steatohepatitis and multiple HCAs with one undergoing malignant transformation. CONCLUSIONS: Normoglycemia alone cannot prevent hepatic steatosis and glycogen accumulation or the development of HCAs in GSD-Ib, providing one explanation why GSD-Ib patients maintaining normoglycemia under intense dietary therapy continue at risk for this long-term complication.
BACKGROUND/AIMS: Glycogen storage disease type Ib (GSD-Ib) patients deficient in a glucose-6-phosphate transporter (G6PT) manifest disturbed glucose homeostasis, myeloid dysfunctions, and hepatocellular adenoma (HCA). This study was conducted to evaluate whether maintaining normoglycemia in GSD-Ib could prevent HCA. METHODS: We infused neonatal GSD-Ib mice with adeno-associated virus (AAV) carrying G6PT and examined their metabolic and myeloid phenotypes for the 72-week study. RESULTS: The AAV vector delivered the G6PT transgene to the liver and bone marrow. Long-term metabolic correction was achieved alongside a transient myeloid correction. Hepatic G6PT activity was 50% of wild-type levels at 2 weeks post-infusion but declined rapidly thereafter to reach 3% of wild-type levels by age 6 to 72 weeks. Despite this, the infused mice maintained normoglycemia throughout the study, exhibited near normal growth and normalized serum metabolite profiles. However, all five AAV-treated GSD-Ib mice that lived over 50 weeks accumulated excessive hepatic glycogen and fat. Two mice developed steatohepatitis and multiple HCAs with one undergoing malignant transformation. CONCLUSIONS: Normoglycemia alone cannot prevent hepatic steatosis and glycogen accumulation or the development of HCAs in GSD-Ib, providing one explanation why GSD-Ib patients maintaining normoglycemia under intense dietary therapy continue at risk for this long-term complication.
Authors: Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit Journal: Eur J Pediatr Date: 2002-08-22 Impact factor: 3.183
Authors: Li-Yuan Chen; Jeng-Jer Shieh; Baochuan Lin; Chi-Jiunn Pan; Ji-Liang Gao; Philip M Murphy; Thomas F Roe; Shimon Moses; Jerrold M Ward; Eric J Lee; Heiner Westphal; Brian C Mansfield; Janice Yang Chou Journal: Hum Mol Genet Date: 2003-08-12 Impact factor: 6.150
Authors: Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson Journal: Proc Natl Acad Sci U S A Date: 2002-08-21 Impact factor: 11.205
Authors: Sun Young Ahn; Soo Young Park; Young Oh Kweon; Won Young Tak; Han Ik Bae; Seung Hyun Cho Journal: World J Gastroenterol Date: 2013-11-14 Impact factor: 5.742
Authors: Joon Hyun Kwon; Young Mok Lee; Jun-Ho Cho; Goo-Young Kim; Javier Anduaga; Matthew F Starost; Brian C Mansfield; Janice Y Chou Journal: Hum Mol Genet Date: 2017-11-15 Impact factor: 6.150